Using a technology called VirScan to study coronavirus antibody responses in a large cohort of SARS-CoV-2-infected and control individuals, researchers identified epitopes recognized by a large fraction of COVID-19 patients, epitopes cross-reactive with antibodies developed in response to other human coronaviruses, and 10 epitopes likely recognized by neutralizing antibodies.
They used this VirScan data to design a tool for rapid SARS-CoV-2 antibody detection. The clinical course of COVID-19 is notable for its extreme variability. Understanding the factors influencing this spectrum of outcomes – including the variable human immune – is an area of focus.
Ellen Shrock and colleagues used a technology known as VirScan – a tool members of the same group developed previously – to explore the antibody response to SARS-CoV-2 and other human coronaviruses in more than 200 COVID-19 patients and nearly 200 pre-COVID-19 era controls.
Blood serum from COVID-19